LoadingLoadingLoadingNet buying: insiders sold $0 and bought $2.6M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
D1 Capital
$116.6M
bought
Sells/Trims (2)
Two Sigma
$83.2M
trimmed
Millennium
$49.8M
trimmed
Buys (3)
Jenisch Jan Philipp
$1.3M
bought
Gibson Dwight Audley Konrad
$244
bought
Sanche Jacques Wolf
$187K
bought
No tracked top-trader positions in AMRZ as of Oct 23, 02:40 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Financial period
Q2 2026
Earnings per share
$0.95 expected
Revenue
Financial statements: Alpha Vantage
FY2026 guidance
$12.50B to $12.70B
No comparable estimate
Estimates as of Oct 22, 2026
EPS expected
$0.88 to $1.06
Revenue expected
13 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $0.88 / $0.95Yahoo Finance | -7.43% miss | $3.49B No estimate | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | -$0.16 / -$0.13Yahoo Finance | -18.82% miss | $2.18B No estimate | Unavailable |
| Dec 31, 2025 | Feb 17, 2026 | $0.62 / $0.62Yahoo Finance | -0.12% in line | $2.84B No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $1.13 / $1.03Yahoo Finance | +10.22% beat | $3.67B No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $0.78 / $1.13Alpha Vantage | -30.97% miss | $3.22B No estimate | Unavailable |
| Mar 31, 2025 | May 28, 2025 | Unavailable | - | $2.08B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.67B | $2.84B | $2.18B | $3.49B |
| Cost of what it sold | $2.59B | $2.08B | $1.97B | $2.50B |
| Gross profit | $1.09B | $760.0M | $211.0M | $993.0M |
| What it spent | ||||
| Sales and admin | $312.0M | $278.0M | $292.0M | $283.0M |
| Total operating expenses | $312.0M | $278.0M | $292.0M | $283.0M |
| What was left | ||||
| Operating profit | $774.0M | $482.0M | -$81.0M | $710.0M |
| Interest on debt | $89.0M | $85.0M | $70.0M | $89.0M |
| Profit before tax | $693.0M | $398.0M | -$145.0M | $622.0M |
| Tax | $150.0M | $100.0M | -$27.0M | $146.0M |
| Net profit | $545.0M | $298.0M | -$116.0M | $478.0M |
| EBITDA | $1.00B | $717.0M | $161.0M | $967.0M |
This stock's price action is mixed, and looks overbought after a fast run-up.
Trend
Mixed
40 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bearish
Amrize Announces Date for Third Quarter 2026 Financial Results
NeutralOct 14Amrize Ltd News — BX:AMRZ
NeutralOct 12Analysts Conflicted on These NA Names: Amrize Ltd (AMRZ) and First Tracks Biotherapeutics Inc (TRAX)
BearishOct 10Amrize stock pre-market at EUR 33.01: minus 0.36 percent
Leans bearishOct 7Analysts Offer Insights on NA Companies: Amrize Ltd (AMRZ) and Wealthfront Corporation (WLTH)
Leans bearishOct 6
